Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2001
03/06/2001US6197347 Oral dosage for the controlled release of analgesic
03/06/2001US6197345 Thrombolytic agents and methods of treatment for thrombosis
03/06/2001US6197344 Butorphanol sustained release formulations
03/06/2001US6197341 Formulations of balsalazide and its derivatives
03/06/2001US6197340 Controlled release lipoic acid
03/06/2001US6197339 Dihydro-5-methylamino-4h-imidazo(4,5-ij)quinoline-2(1h)one butenedioate with starches and hydroxypropyl cellulose
03/06/2001US6197336 Ibuprofen with arginine and polyvinylpyrrolidone
03/06/2001US6197332 Lipid-conjugated polyamide compounds and related compositions and methods thereof
03/06/2001US6197329 Anti-nausea compositions and methods
03/06/2001US6197327 Device and method for treatment of dysmenorrhea
03/06/2001US6197324 Implanting local anesthetic into myocardial tissue
03/06/2001US6197317 Composition and method for the treatment of skin
03/06/2001US6197314 Impeding the extraction of active ingredients out of tablets
03/06/2001US6197309 Mixture containing vitamins, minerals, plant extracts and amino acids
03/06/2001US6197306 Herbal composition for the treatment of chronic obstructive pulmonary disease, bronchitis and respiratory disorders and a process for preparing the same
03/06/2001US6197300 ftsZ
03/06/2001US6197290 Anion exchange resin-containing tablets
03/06/2001US6197069 Adrenomedullin receptor polynucleotides
03/06/2001CA2223081C Heterocyclic ring-fused pyrimidine derivatives
03/06/2001CA2183655C 4-polycyclic amino-substituted quinazoline derivatives
03/06/2001CA2132416C Use of transglutaminase inhibitor for the treatment of scar tissue
03/06/2001CA2081113C Thiazolidine-2,4-dione derivative, salt thereof, and production of the same
03/06/2001CA2073673C Esters of 2-arylmethyl-1-naphthol derivatives as 5-lipoxygenase inhibitors
03/06/2001CA2010635C Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
03/06/2001CA1341201C Bis-(hydroxymethyl) cyclobutyl purines and pyrimidines
03/06/2001CA1341196C Process for the preparation of substituted imino diacids
03/01/2001WO2001014886A2 Inhibitors of binding between proteins and macromolecular ligands
03/01/2001WO2001014576A2 Process and intermediates for the preparation of isoxazolecaroxamides and analogues
03/01/2001WO2001014551A1 NOVEL bHLH TYPE TRANSCRIPTION FACTOR GENE DEC2
03/01/2001WO2001014549A1 Gas1 polypeptides
03/01/2001WO2001014536A2 Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, and comprising at least one intron sequence
03/01/2001WO2001014535A2 UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-β1,3-N-ACETYLGALACTOSAMINE-α-R/(GlcNAc to GalNAc) β1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3
03/01/2001WO2001014468A1 Alginate preparation and use of the same
03/01/2001WO2001014418A2 p193 PROTEINS AND NUCLEIC ACIDS, AND USES THEREOF
03/01/2001WO2001014415A2 Egfh2 genes and gene products
03/01/2001WO2001014414A2 Human abc2 transporter and uses thereof
03/01/2001WO2001014405A2 Methods of obtaining 2-methoxyestradiol of high purity
03/01/2001WO2001014402A1 Antisense modulation of focal adhesion kinase expression
03/01/2001WO2001014401A1 Nucleoside pyrophosphate and triphosphate analogs and related compounds as therapeutic agents
03/01/2001WO2001014400A1 2'-o-acetamido modified monomers and oligomers
03/01/2001WO2001014399A1 Novel a-500359 derivatives
03/01/2001WO2001014397A1 9a-azalides with antibacterial activity
03/01/2001WO2001014396A1 Flavonoids derived from citrus peels as collagen-induced platelet aggregation inhibitor
03/01/2001WO2001014393A2 Spherical telithromycin clusters, method for the production and use thereof in the preparation of pharmaceutical forms
03/01/2001WO2001014383A1 Remedies for neuropathic pain and model animals of neuropathic pain
03/01/2001WO2001014380A1 Isomeric fused pyrrolocarbazoles and isoindolones
03/01/2001WO2001014377A1 Imidazo-triazine derivatives as ligands for gaba receptors
03/01/2001WO2001014376A1 Novel spiro compounds
03/01/2001WO2001014375A1 Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives
03/01/2001WO2001014372A2 Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
03/01/2001WO2001014371A1 N-heterocyclic derivatives as nos inhibitors
03/01/2001WO2001014368A1 Compounds, compositions and methods for treating influenza
03/01/2001WO2001014367A1 Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
03/01/2001WO2001014365A1 COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING bcl-2 FAMILY MEMBER PROTEINS
03/01/2001WO2001014364A1 Fatty acid synthase inhibitors
03/01/2001WO2001014363A1 Fatty acid synthase inhibitors
03/01/2001WO2001014362A1 Fatty acid synthase inhibitors
03/01/2001WO2001014360A2 Benzopyrans and benzothiopyrans as rar selective retinoid agonists
03/01/2001WO2001014358A2 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans
03/01/2001WO2001014355A1 Substituted piperazine derivatives, the production thereof and their utilization as medicaments
03/01/2001WO2001014354A1 Substituted 2-arylbenzazole compounds and their use as antitumour agents
03/01/2001WO2001014353A1 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents
03/01/2001WO2001014347A1 Benzoxazine and benzothiazine derivatives and the use thereof in medicaments
03/01/2001WO2001014342A1 Aminocarbonyl-substituted benzimidazole derivatives, method for producing same and the use thereof as medicaments
03/01/2001WO2001014341A1 Agents for controlling animal diseases caused by parasites
03/01/2001WO2001014340A1 Agents for controlling animal diseases caused by endoparasites
03/01/2001WO2001014338A1 NOVEL INTEGRIN αVβ3 INHIBITORS
03/01/2001WO2001014337A1 αvβ3 INTEGRIN INHIBITORS
03/01/2001WO2001014333A1 Substituted piperidine compounds useful as modulators of chemokine receptor activity
03/01/2001WO2001014332A1 Piperidine alcohols
03/01/2001WO2001014331A2 Non-quinoline inhibitors of malaria parasites
03/01/2001WO2001014330A2 Phenylpiperazines as serotonin reuptake inhibitors
03/01/2001WO2001014324A1 Selective inhibitors of the urokinase plasminogene activators
03/01/2001WO2001014320A1 Compounds that inhibit tryptase activity
03/01/2001WO2001014318A2 New effectors of dipeptidyl peptidase iv for topical use
03/01/2001WO2001014316A1 Substituted chiral allosteric hemoglobin modifiers
03/01/2001WO2001014043A1 Immobilisation of a biocide on activated carbon
03/01/2001WO2001014036A1 Process for producing fine medicinal substances
03/01/2001WO2001013957A2 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
03/01/2001WO2001013954A1 Method of treating body insect infestation
03/01/2001WO2001013953A2 Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
03/01/2001WO2001013952A1 Preventives/remedies for heart failure
03/01/2001WO2001013950A1 Percutaneous absorption agents
03/01/2001WO2001013949A2 Medical preparation for treating arthrosis, arthritis and other rheumatic joint diseases
03/01/2001WO2001013935A2 Modulation of the blood-brain barrier transporter for leptin
03/01/2001WO2001013933A2 Agents for the enhanced oxygen delivery in mammals
03/01/2001WO2001013932A2 Stimulation of sperm function
03/01/2001WO2001013927A2 Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof
03/01/2001WO2001013925A1 Remedies
03/01/2001WO2001013924A1 Novel compositions for controlled release of a biologically active agent, and the preparation thereof
03/01/2001WO2001013923A1 Malaria gpi anchors as vaccines anti-parasitic drugs and for use in diagnostics
03/01/2001WO2001013922A1 Drug for treating fractures
03/01/2001WO2001013921A1 Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms
03/01/2001WO2001013920A1 Carnitine analogues as topical, microbicidal spermicides
03/01/2001WO2001013919A1 Ft-raman spectroscopic measurement of omeprazole isomer ratio in a composition
03/01/2001WO2001013918A1 Treatment of urinary incontinence
03/01/2001WO2001013917A1 Npy antagonists: spiroisoquinolinone derivatives
03/01/2001WO2001013915A1 Cataplasms containing vitamin c or its derivative
03/01/2001WO2001013913A1 Compositions containing esters for treating parasitic infestations of organisms
03/01/2001WO2001013912A1 Remedies for liver regeneration of transplanted liver